Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | SHBG | P04278 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.34 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | ESRRB | O95718 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2602642 | 0.87 | ESR1 (0.39) | ESR1ESR2LMNAMAPK1SHBG | |
| SCHEMBL2602633 | 0.86 | ESR1 (0.38) | ESR1ESR2LMNAMAPK1SHBG | |
| SCHEMBL2602653 | 0.83 | ESR1 (0.36) | ESR1ESR2LMNAMAPK1SHBG | |
| SCHEMBL2602632 | 0.80 | ESR1 (0.46) | ESR1ESR2LMNASHBGHSD17B10 | |
| SCHEMBL5854103 | 0.80 | ESR1 (0.46) | ESR1ESR2LMNASHBGHSD17B10 | |
| SCHEMBL2602639 | 0.77 | CYP19A1 (0.37) | ESR1ESR2LMNAMAPK1MEN1 | |
| SCHEMBL2602644 | 0.77 | ESR2 (0.33) | ESR1ESR2LMNAMAPK1CYP2C19 | |
| SCHEMBL2605880 | 0.76 | CYP19A1 (0.40) | ESR1ESR2LMNAMAPK1SHBG | |
| SCHEMBL2602650 | 0.74 | CYP19A1 (0.37) | ESR1ESR2CYP19A1 | |
| SCHEMBL2602647 | 0.74 | SHBG (0.42) | ESR1ESR2LMNAMAPK1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952073-B2 | Estrogenic compounds, process for their production and pharmaceutical uses thereof | UNIVERSITY OF OTTAWA (CA) | 2015-02-10 | — | — | US | disclosed |
| US-8952073-B2 | Estrogenic compounds, process for their production and pharmaceutical uses thereof | UNIVERSITY OF OTTAWA (CA) | 2015-02-10 | — | — | US | disclosed |
| US-20130274344-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2013-10-17 | — | — | US | disclosed |
| US-20130274344-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2013-10-17 | — | — | US | disclosed |
| US-8471073-B2 | Estrogenic compounds, process for their production and pharmaceutical uses thereof | UNIVERSITY OF OTTAWA (CA) | 2013-06-25 | — | — | US | disclosed |
| US-8471073-B2 | Estrogenic compounds, process for their production and pharmaceutical uses thereof | UNIVERSITY OF OTTAWA (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20120190898-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | SHADNIA HOOMAN (CA) | 2012-07-26 | — | — | US | disclosed |
| US-20120190898-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | SHADNIA HOOMAN (CA) | 2012-07-26 | — | — | US | disclosed |
| US-8158684-B2 | Estrogenic compounds, process for their production and pharmaceutical uses thereof | UNIVERSITY OF OTTAWA (CA) | 2012-04-17 | — | — | US | disclosed |
| US-8158684-B2 | Estrogenic compounds, process for their production and pharmaceutical uses thereof | UNIVERSITY OF OTTAWA (CA) | 2012-04-17 | — | — | US | disclosed |
| US-20110196045-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20110196045-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20090234024-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | SHADNIA HOOMAN | 2009-09-17 | — | — | US | disclosed |
| US-20090234024-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | SHADNIA HOOMAN | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196045-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | CYP19A1, ESR1, ESR2 | ESR1 2/4885ESR2 3/4885LMNA 2822/4885 |
| US-20120190898-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | CYP19A1, ESR1, ESR2 | ESR1 2/4885ESR2 3/4885LMNA 2822/4885 |
| US-20130274344-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | CYP19A1, ESR1, ESR2 | ESR1 2/4885ESR2 3/4885LMNA 3762/4885 |
| US-20090234024-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | CYP19A1, ESR1, ESR2 | ESR1 2/4885ESR2 3/4885LMNA 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.